



Date: January 06, 2024

To  
The Manager  
Corporate Relations Department  
BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street  
Mumbai – 400001

Dear Sir/Madam,

**Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018**

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Allotment of 9,25,000 Equity Shares pursuant to exercise of warrants allotted on preferential basis.**

**Ref: Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular's SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and CIR/CFD/CMD/4/2015 dated September 09, 2015.**

This is in furtherance to the intimation given by the Company on 13<sup>th</sup> October 2022 w.r.t. allotment of 37,00,000 share warrants convertible into equity shares having a face value of Rs. 10/- each at a premium of Rs. 5/- (Rupees Five Only) each within a period of 18 months from the date of allotment of warrants, as per terms and conditions approved in AGM held on 20<sup>th</sup> August, 2022, upon receiving of upfront 25% of the total consideration to five allottees.

In accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations, 2015'), we wish to inform you that Dr. Prasad S and Ms. Mini Manikantan ("Warrant Holders"), are the remaining two warrants holder who were yet to exercise their options for conversion.

The Company received the request letter and balance consideration i.e. 75% of the total consideration on 03<sup>rd</sup> January 2023 requesting for conversion of 9,25,000 Share Warrants into equal number of Equity Shares as per terms of issue.

Upon receipt of an amount aggregating to Rs. 1,04,06,250/- (being 75% of the total consideration payable), the Board at its meeting held today i.e. January 06, 2024, has approved the conversion and allotment of 9,25,000 Equity Shares of Rs. 10/- each, to the aforesaid mentioned allottees (other than the Promoters and Promoter Group) upon conversion of equal number of Warrants.



# Pharmaids Pharmaceuticals Limited

After the said conversion, there are no other share warrants outstanding for conversion. The new Equity Shares so allotted shall rank pari passu with the existing Equity Shares of the Company in all respects.

The details as required under Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given in **Annexure – A** to this letter.

Kindly take the same on your record and oblige.

Thanking You

**For Pharmaids Pharmaceuticals Limited**

**Kaushik Kumar**

**(Company Secretary & Head-Legal)**



# Pharmaids Pharmaceuticals Limited

Annexure A

**Disclosures in terms of Regulation 30 of the Listing Regulations read with the SEBI Disclosure Circular, in respect of Issue of equity shares to the Warrant holders.**

Sr. No	Particulars	Details						
a	Type of securities proposed to be issued (viz. equity shares, convertibles, etc.)	Equity Shares pursuant to conversion of warrants.						
b	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential allotment.						
c	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately).	Allotment of 9,25,000 Equity Shares of face value of Rs. 10/- each pursuant to conversion of Share Warrants.						
d	Names of the investors	1. Dr. Prasad S 2. Ms. Mini Manikantan						
e	Post-Allotment of Securities: Outcome of Subscription	<b>Sr. No</b>	<b>Name of the proposed allottees</b>	<b>Pre-Issue Shareholding</b>		<b>No. of Shares allotted Upon conversion of warrants</b>	<b>Post Issue Shareholding</b>	
				<b>No. of Shares</b>	<b>% of Shareholding</b>		<b>No. of Shares</b>	<b>% of Shareholding</b>
		1	Dr. Prasad S	201	0.001	4,25,000	4,25,201	1.90
		2	Ms. Mini Manikantan	Nil	Nil	5,00,000	5,00,000	2.23
f	Issue Price / Allotted Price (in case of convertibles)	Rs. 15/- per share.						
g	Number of investors	2						
h	In case of convertibles: intimation of conversion of	An amount equivalent to 25% of the Warrant Issue Price has been received at the time of subscription and allotment of each Warrant and the balance 75% is now also paid by the warrant holder(s) mentioned						

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979)

Registered Office.: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA Phone: 080-49784319 Email: [compliance@pharmaids.com](mailto:compliance@pharmaids.com) WEB: [www.pharmaids.com](http://www.pharmaids.com)



# Pharmaids Pharmaceuticals Limited

securities or on lapse of the tenure of the instrument	above on the exercise of warrant(s) within the period of 18 months as prescribed under SEBI (ICDR) Regulations, 2018. Accordingly, the warrants have been converted into equity shares and allotted to the above mentioned allottees.
--	---

**For Pharmaids Pharmaceuticals Limited**

**Kaushik Kumar**

**(Company Secretary & Head-Legal)**